The company presented new findings at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases in Barcelona, Spain, held May 4-7, 2023.
Bioiberica (Barcelona, Spain) says new unpublished research suggests that its proprietary Mobilee hyaluronic acid matrix ingredient, which has been clinically shown to support mobility health, may also help support muscle health and play a role against sarcopenia, or age-related muscle decline. The company presented these new findings at the World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases held in Barcelona, Spain, on May 4-7, 2023.
“The aim of the present research was to evaluate the effect of Mobilee on muscle health specifically, using in vitro models of health and sarcopenia,” a Bioiberica press release states.
In the study, myocytes, or muscle cells, were treated with 6 µg/ml of Mobilee for 24 hours. Researchers evaluated the “proliferation and hyperplasia of myocytes” in order to determine potential effects on muscle homeostasis and whether Mobilee might protect against muscle damage and atrophy.
According to the company, “The results showed that Mobilee promoted myocyte hyperplasia (increase in myocyte size) by 7% and myocyte proliferation (production of new cells) by more than 20%. The ingredient also showed an effect against muscle atrophy, muscle damage, and cell death in the sarcopenia model.”
The company says it is one of the few studying the effects of hyaluronic acid on muscle health. “Mobilee is the result of 15-plus years of research and development and is backed by robust scientific research demonstrating its unique benefits in joint and muscle health,” said Daniel Martinez-Puig, head of R&D, human health, for Bioiberica, in the press release. “The latest evidence points towards its potential to play a supportive role in muscles, too, where it may be effective for balancing muscle cell turnover and protecting against common characteristics of sarcopenia.”